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Advances cholangiocarcinoma is associated with severely impaired survival prognosis and limited treatment option. Mutation of the isocitrate dehydrogenase 1 (IDH1) occurs in up to 20% of patients with cholangiocarcinoma. The ClarIDHy trial was a randomised, double blind phase trials of the IDH inhibitor ivosidenib in patients with advanced cholangiocarcinoma. The competitor arm was placebo. Progression-free survival was 2.7 vs 1.4 months. The present podcast discusses the ClarIDHy trial as well as the impact of the results on the standard treatment of patients with advanced cholangiocarcinoma.
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